Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain
NCT03342950 · Terence J. Coderre · PHASE2 · terminated · last registry update 2021-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment due to the COVID-19 pandemic” | – | Registry record, Terence J. Coderre |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-07Results posted on the registry: Q2i, LLC, a drug against SCN1A (NCT05159362)
- 2022-09-22Phase 3 first posted: Mohammed Ghassan Mohammed Shaalan, a drug against SCN1A (NCT05550285)
- 2022-09-09Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786-18 + Placebo (NCT02442778)
- 2022-08-11Results posted on the registry: Johns Hopkins University, a drug against SCN1A (NCT02487745)
- 2022-07-29Phase 3 first posted: Nobelpharma, NPC-06 + Placebo (NCT05480553)
- 2022-06-29Also stopped (withdrawn): Tonix Pharmaceuticals, Inc., TNX-1300 (NCT04996056)
- 2022-06-27Also stopped (withdrawn): Assistance Publique Hopitaux De Marseille, Perampanel + conventional antiepileptic treatment (NCT03636958)
- 2022-06-27Results posted on the registry: The University of Texas Health Science Center, Houston, Exenatide 2 mg [Bydureon] (NCT04941521)
- 2022-06-03Also stopped (terminated): Vanderbilt University, (R)-propafenone + (S)-Propafenone (NCT02710669)
- 2022-05-24Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT03420222)
- 2022-05-24Also stopped (terminated): Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT03420222)
- 2022-05-18Also stopped (withdrawn): Centers for Disease Control and Prevention, Pyridoxine + Sodium Valproate (NCT01730313)
- 2022-05-02Also stopped (withdrawn): University of Miami, a drug against SCN1A (NCT05223881)
- 2022-04-29Results posted on the registry: Avanir Pharmaceuticals, AVP-923-45 + Placebo (NCT01767129)
- 2022-04-29Also stopped (terminated): Mansoura University, Orphenadrine + Baclofen (NCT04509336)
- 2022-04-22Also stopped (withdrawn): Centre Hospitalier Henri Laborit, a drug against SCN1A (NCT05341934)
- 2022-03-24Phase 3 first posted: Universitätsklinikum Hamburg-Eppendorf, a drug against SCN1A (NCT05293080)
- 2022-01-25Results posted on the registry: New York State Psychiatric Institute, Mixed-Amphetamine Salts- Extended Release (MAS-ER) + Placebo (NCT01986075)
- 2021-11-30Results posted on the registry: UConn Health, a drug against SCN1A (NCT02143063)
- 2021-09-20Results posted on the registry: Johns Hopkins University, Placebo + Bupropion XL (NCT02111798)
- 2021-05-14Results posted on the registry: Vanderbilt University, (R)-propafenone + (S)-Propafenone (NCT02710669)
- 2021-03-17Phase 3 first posted: Milton S. Hershey Medical Center, Shampoo and saline + Saline and Listerine (NCT04802408)
- 2021-03-10Phase 3 first posted: LXO Ireland, Cocaine Hydrochloride Nasal Solution + Cocaine Hydrochloride Nasal Solution (NCT04792034)
- 2020-12-01Phase 3 first posted: David J. Kopsky, phenytoin cream (NCT04647877)
- 2020-10-26Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02534038)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision